- Conditions
- Secondary Immune Deficiency
- Interventions
- IgPro20
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 17
- States / cities
- Orange, California • Denver, Colorado • Coral Springs, Florida + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 297
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV Infections, Cytopenias
- Interventions
- Epoetin alfa
- Drug
- Lead sponsor
- Ortho Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Raritan, New Jersey
- Conditions
- Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Gastrointestinal Stromal Tumors, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Central Nervous System Tumor, Central Nervous System Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control
- Interventions
- Not listed
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 110 Years
- Enrollment
- 999,999 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2099
- U.S. locations
- 42
- States / cities
- Greenwood Village, Colorado • Manchester, Connecticut • Daytona Beach, Florida + 34 more
- Conditions
- Immune Deficiency Disorders, Severe Combined Immunodeficiency, Chronic Granulomatous Disease, X-linked Agammaglobulinemia, Wiskott-Aldrich Syndrome, Hyper-IgM, DiGeorge Syndrome, Chediak-Higashi Syndrome, Common Variable Immune Deficiency, Immune Dysregulatory Disorders, Hemophagocytic Lymphohistiocytosis, IPEX, Autoimmune Lymphoproliferative Syndrome, X-linked Lymphoproliferative Syndrome
- Interventions
- Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Myelokathexis, Infections, Neutropenia, Warts, Hypogammaglobulinemia
- Interventions
- Plerixafor, G-CSF
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 10 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Body Composition, Beneficial, Paresis, Impaired Glucose Tolerance
- Interventions
- wt loss, meal pattern, even, skew
- Other · Dietary Supplement
- Lead sponsor
- Purdue University
- Other
- Eligibility
- 19 Years to 50 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- West Lafayette, Indiana
- Conditions
- Human Immunodeficiency Virus
- Interventions
- Ad26.Mos4.HIV, MVA-Mosaic, Clade C gp140 + Mosaic gp140, Placebo
- Biological · Drug
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Primary Immune Deficiencies, Autoimmune Diseases, Inflammatory Diseases, Common Variable Immune Deficiencies, Hypogammaglobulinemia
- Interventions
- Not listed
- Lead sponsor
- O & O Alpan LLC
- Other
- Eligibility
- 1 Day and older
- Enrollment
- 343 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Fairfax, Virginia
- Conditions
- Primary Immune Deficiency Disorders, Common Variable Immunodeficiency, X-linked Agammaglobulinaemia, Hyperimmunoglobulin M Syndrome
- Interventions
- Subgam
- Biological
- Lead sponsor
- Bio Products Laboratory
- Other
- Eligibility
- 2 Years to 75 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 16
- States / cities
- Chandler, Arizona • Irvine, California • San Diego, California + 12 more
- Conditions
- Diabetic Nephropathy, Proteinuria, Oxidative Stress
- Interventions
- N-acetylcysteine placebo and silibin placebo, N-acetylcysteine active and silibin placebo, N-acetylcysteine placebo and silibin active, N-acetylcysteine active and silibin active, N-acetylcysteine active + high-dose silibin active
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 76 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Hemophilia B
- Interventions
- Adeno-Associated Viral with Human Factor IX
- Genetic
- Lead sponsor
- Avigen
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 3
- States / cities
- Palo Alto, California • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Navlimetostat, Pumitamig
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- HIV Infections
- Interventions
- env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, Placebo, GLA-SE adjuvant
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Decatur, Georgia • Boston, Massachusetts + 3 more
- Conditions
- Alpha1-Antitrypsin Deficiency
- Interventions
- Fazirsiran Injection, Placebo
- Drug · Other
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 28 more
- Conditions
- HIV Infections
- Interventions
- Zidovudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 538 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1990
- U.S. locations
- 23
- States / cities
- Los Angeles, California • San Diego, California • Stanford, California + 16 more
- Conditions
- HIV Infections, HIV Wasting Syndrome
- Interventions
- Optimune oral nutritional supplement
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 18
- States / cities
- Los Angeles, California • San Francisco, California • Stanford, California + 12 more
- Conditions
- HIV Infections
- Interventions
- CD4-IgG, Zidovudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 3
- States / cities
- San Diego, California • Miami, Florida • Worcester, Massachusetts
- Conditions
- HIV Infections
- Interventions
- gp160 Vaccine (Immuno-AG)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 1995
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • Seattle, Washington
- Conditions
- Hemophilia A, Hemophilia B, Vitamin D Deficiency
- Interventions
- Vitamin D and calcium
- Dietary Supplement
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 2 Years to 21 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Factor XIII Deficiency
- Interventions
- FXIII Concentrate (Human) (FXIII)
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- Not listed
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 25
- States / cities
- Dothan, Alabama • Oakland, California • Orange, California + 22 more
- Conditions
- Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Interventions
- Gamunex-C, 10% Injectable Solution
- Drug
- Lead sponsor
- Grifols Biologicals, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 5
- States / cities
- St. Petersburg, Florida • Fort Wayne, Indiana • Westbrook, Maine + 2 more
- Conditions
- Hypoalbuminemia, Protein-energy Malnutrition, Inflammation, Oxidative Stress, Chronic Kidney Disease (CKD) Hemodialysis
- Interventions
- pentoxiphylline, Nepro, anti-inflammatory module (similar to Oxepa), Placebo pill imitating pentoxiphylline, Placebo to imitate Nepro, Placebo to imitate anti-inflammatory module (similar to Oxepa)
- Drug · Dietary Supplement
- Lead sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 2
- States / cities
- Irvine, California • Torrance, California
- Conditions
- GLUT1DS1, Epilepsy, Glut1 Deficiency Syndrome 1, Autosomal Recessive, Glucose Metabolism Disorders, Glucose Transport Defect, Glucose Transporter Type 1 Deficiency Syndrome, Glucose Transporter Protein Type 1 Deficiency Syndrome
- Interventions
- Triheptanoin
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 24 Months to 35 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- HIV Infections
- Interventions
- Recombinant interleukin-2 (rIL-2)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 4,150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2008
- U.S. locations
- 78
- States / cities
- Los Angeles, California • Mill Valley, California • Oakland, California + 33 more